Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Melanoma × Radiotherapy × 30 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 11 Glioblastoma 10 Prostatic Neoplasms 8 Lung Neoplasms 8 Carcinoma, Non-Small-Cell Lung 8 Squamous Cell Carcinoma of Head and Neck 7 Glioma 7 Head and Neck Neoplasms 5 Uterine Cervical Neoplasms 4 Urinary Bladder Neoplasms 4 Sarcoma 4 Oropharyngeal Neoplasms 4 Neoplasms 4 Colorectal Neoplasms 4 Brain Neoplasms 4 Rectal Neoplasms 3 Radiation Injuries 3 Esophageal Neoplasms 3 Carcinoma 3 Astrocytoma 3 Vaginal Neoplasms 2 Triple Negative Breast Neoplasms 2 Small Cell Lung Carcinoma 2 Rhabdomyosarcoma, Embryonal 2 Rhabdomyosarcoma 2 Recurrence 2 Nasopharyngeal Carcinoma 2 Mouth Neoplasms 2 Liposarcoma 2 Leiomyosarcoma 2

Interventions

pembrolizumab 32 Nivolumab 28 Ipilimumab 17 Specimen Handling 14 Magnetic Resonance Spectroscopy 12 trametinib 10 Cyclophosphamide 9 Biopsy 9 CTLA-4 Antigen 7 fludarabine 5 dabrafenib 5 relatlimab 4 encorafenib 4 binimetinib 4 aldesleukin 4 Introns 4 Interleukin-2 4 Interferon alpha-2 4 naporafenib 3 fludarabine phosphate 3 cabozantinib 3 atezolizumab 3 Vemurafenib 3 Radiosurgery 3 Opdualag 3 tocilizumab 2 sargramostim 2 ribociclib 2 cobimetinib 2 aflibercept 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04594187 2026-02-17

MelPORT

M.D. Anderson Cancer Center

Phase 2 Recruiting

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡